Published Date: 03 May 2024
Staff members of MedPage Today have compiled health news and opinions.
Read Full NewsAbdominal and chest pain. Injuries. Breathing difficulty. Infections. Mental health emergencies. Those are some of the most common reasons why people go to the local emergency department.
University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that's on the rise in American women, is often more difficult to detect than ...
Cancer treatment has come a long way, but many of today's therapies still come with steep costs: not just financial, but physical and emotional too. Chemotherapy and radiotherapy remain vital tools, yet they often damage ...
1.
For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.
2.
Australian researchers attribute drop in melanoma rates to increasingly diverse population
3.
a brand-new generic therapy for different types of cancer.
4.
What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care
5.
Traveling to Die: The Latest Form of Medical Tourism
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
3.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
4.
Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management
5.
Revolutionizing Cancer Care with Fulphila: A New Hope for Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Navigating the Complexities of Ph Negative ALL - Part VIII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation